Terns Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced positive data from its Phase 1 study of TERN-601, a novel once-daily oral GLP-1R agonist for the treatment of obesity. The results will be highlighted at the American Diabetes Association's 85th Scientific Sessions, held from June 20-23, 2025, in Chicago, IL. The Phase 1 study demonstrated a differentiated profile for TERN-601, with topline data initially reported in September 2024. Additionally, the company has completed enrollment for its Phase 2 FALCON clinical trial, with 12-week data expected in the fourth quarter of 2025. The trial aims to assess TERN-601's competitive weight loss efficacy, safety, tolerability, and dosing simplicity among GLP-1R agonist therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.